Humacyte Inc (NASDAQ:HUMA) — Market Cap & Net Worth
Market Cap & Net Worth: Humacyte Inc (HUMA)
Humacyte Inc (NASDAQ:HUMA) has a market capitalization of $127.68 Million ($127.68 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18363 globally and #4290 in its home market, demonstrating a -0.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Humacyte Inc's stock price $0.58 by its total outstanding shares 222019108 (222.02 Million). Also see HUMA asset base for a full breakdown of the balance sheet.
Humacyte Inc Market Cap History: 2020 to 2026
Humacyte Inc's market capitalization history from 2020 to 2026. Data shows change from $2.26 Billion to $127.68 Million (-38.54% CAGR). Also see Humacyte Inc (HUMA) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
Humacyte Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #513 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1787 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.01% | #238 of 263 |
Weight: Humacyte Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Humacyte Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Humacyte Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check HUMA share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
104.64x
Humacyte Inc's market cap is 104.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.26 Billion | $1.49 Million | -$66.52 Million | 1514.38x | N/A |
| 2021 | $1.61 Billion | $1.26 Million | -$26.48 Million | 1274.46x | N/A |
| 2022 | $468.46 Million | $1.56 Million | -$11.96 Million | 299.34x | N/A |
| 2025 | $213.25 Million | $2.04 Million | -$40.83 Million | 104.64x | N/A |
Competitor Companies of HUMA by Market Capitalization
Companies near Humacyte Inc in the global market cap rankings as of September 18, 2026. Review Humacyte Inc tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Humacyte Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Humacyte Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Humacyte Inc's market cap moved from $2.26 Billion to $ 127.68 Million, with a yearly change of -38.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $127.68 Million | -40.12% |
| 2025 | $213.25 Million | -80.98% |
| 2024 | $1.12 Billion | +77.82% |
| 2023 | $630.53 Million | +34.60% |
| 2022 | $468.46 Million | -70.90% |
| 2021 | $1.61 Billion | -28.71% |
| 2020 | $2.26 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Humacyte Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $127.68 Million USD |
| MoneyControl | $127.68 Million USD |
| MarketWatch | $127.68 Million USD |
| marketcap.company | $127.68 Million USD |
| Reuters | $127.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more